Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

This Coronavirus Stock Just Got More Attractive: Should You Buy?

TheMotleyFool

0 0

This Coronavirus Stock Just Got More Attractive: Should You Buy?

Few stocks have performed better than Vaxart (NASDAQ: VXRT) of late. Year to date, shares of this company are up by more than 3,400%. And despite these massive gains, Vaxart's market cap is still just $1.34 billion, a reasonable level for a clinical-stage biotech.

Vaxart's efforts to develop an oral vaccine for the novel coronavirus have been instrumental to its performance in the market this year. However, investors will want to pay attention to another opportunity the company is facing, as well.